000			02257cam a2200349 a 4500
003			EG-GiCUC
005			20250223032048.0
008			180922s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.07.M.Sc.2018.Me.E
100	0		_aMenna Alla Mohie Eldein Elsayed Sherif
245	1	0	_aEffect of cyclin D1 on the prognosis of multiple myeloma in Egyptian patients / _cMenna Alla Mohie Eldein Elsayed Sherif ; Supervised Lalia Abdelrahman Hegazy , Osman Mohamed Mansour , Reham Ahmed Rashed
246	1	5	_aعلى التطور الأكلينيكى فى المرضى المصريين المصابين بالورم النقوى المتعدد D1 تأثير السيكلين
260			_aCairo : _bMenna Alla Mohie Eldein Elsayed Sherif , _c2018
300			_a129 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520			_aBackground: Multiple myeloma is a disseminated malignancy of monoclonal plasma cells, diagnosed by {u2265}10% clonal bone marrow plasma cells or a biopsy infiltrated by plasma cells along with one or more of the multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions). Aim of work: Correlating Cyclin D1 with the prognosis of the patients. Subjects, materials and methods: Bone marrow biopsy of 50 patients newly diagnosed as Multiple myeloma were examined by immunohistochemistry for Cyclin D1, then these patients were followed up for a year. Results: There was significant correlation between Cyclin D1 and response of the patients. Conclusion: Cyclin D1 positive patients were found more likely to have worse prognosis than the negative ones
530			_aIssued also as CD
653		4	_aCyclin D1
653		4	_aImmunohistochemistry
653		4	_aMultiple Myeloma
700	0		_aLalia Abdelrahman Hegazy , _eSupervisor
700	0		_aOsman Mohamed Mansour , _eSupervisor
700	0		_aReham Ahmed Rashed , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c67601 _d67601